Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Abbott Laboratories: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Abbott Laboratories
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Abbott Laboratories
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company benefits from high valuations in earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Rating Financials

Abbott Laboratories SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Abbott Laboratories SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Abbott Laboratories SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Abbott Laboratories SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Abbott Laboratories SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
167B
BBB
111B
BBB
105B
AA
74.82B
AA
59.11B
AA
51.8B
AAA
48.5B
A
40.79B
AAA
32.54B
BBB
30.76B
AAA
Average 72.09B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. Ratings Abbott Laboratories